Comparing carboplatin and olaparib for prostate cancer with BRCA gene changes
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital, Kidney & urinary clinical trials.
This study compares two treatments for prostate cancer that has spread and has specific gene changes (BRCA or related genes). It aims to see which treatment works better for people whose cancer has stopped responding to other hormone therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread and is growing despite hormone therapy.
- Your cancer has a change (mutation) in one of these genes: RAD51B, RAD51C, RAD51D, or RAD54L.
- You have already tried a drug like abiraterone, enzalutamide, apalutamide, or darolutamide.
- You are currently on hormone therapy (like GnRH analogues) or have had your testicles removed.
- You have not had prior treatment with platinum chemotherapy, mitoxantrone, or a PARP inhibitor for prostate cancer.
- Your blood counts and organ function are within normal limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called talazoparib, either alone or combined with enzalutamide, in people with prostate cancer that has spread and has a specific genetic change. The goal is to see if this treatment can help control the cancer after previous therapies have stopped working.
This trial studies how well olaparib works for men with metastatic castration-resistant prostate cancer that has a BRCA mutation. It looks at results from real-world use, not a controlled study.
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
This Phase 2 study tests whether adding a medicine called olaparib to radiation helps men with high-risk prostate cancer. You may receive radiation alone or radiation plus olaparib, and the study looks at whether the combination works better.
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
This study looks at how well the combination of two drugs, olaparib and abiraterone, works for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if this treatment helps patients live longer and feel better in real-world settings.
Hear when a new Metastatic Castrate Resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.